DE60120648D1 - Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung - Google Patents

Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung

Info

Publication number: DE60120648D1
Authority: DE; Germany
Prior art keywords: copolymer; glatirameracetate; nasal; formulations; oral
Prior art date: 2000-02-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60120648T

Other languages

English (en)

Inventor

Adrian Gilbert

Rivka Riven-Kreitman

Milka Linenberg

Sharon Cohen-Vered

F Joubran

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yeda Research and Development Co Ltd

Original Assignee

Yeda Research and Development Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-18

Filing date

2001-02-16

Publication date

2006-07-27

2001-02-16 Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd

2006-07-27 Application granted granted Critical

2006-07-27 Publication of DE60120648D1 publication Critical patent/DE60120648D1/de

2021-02-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurology (AREA)
Dermatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)
Polyethers (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE60120648T 2000-02-18 2001-02-16 Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung Expired - Lifetime DE60120648D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18366600P	2000-02-18	2000-02-18
US50718800A	2000-02-18	2000-02-18
PCT/US2001/005198 WO2001060392A1 (en)	2000-02-18	2001-02-16	Oral, nasal and pulmonary dosage formualtions of copolymer 1

Publications (1)

Publication Number	Publication Date
DE60120648D1 true DE60120648D1 (de)	2006-07-27

Family

ID=26879409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60120648T Expired - Lifetime DE60120648D1 (de)	2000-02-18	2001-02-16	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung

Country Status (10)

Country	Link
EP (1)	EP1261361B1 (de)
JP (1)	JP2003522799A (de)
CN (1)	CN1221281C (de)
AT (1)	ATE329608T1 (de)
AU (2)	AU2001238469C1 (de)
CA (1)	CA2400374A1 (de)
DE (1)	DE60120648D1 (de)
IL (1)	IL150895A0 (de)
MX (1)	MXPA02008023A (de)
WO (1)	WO2001060392A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2337688C (en)	1998-07-23	2016-04-05	Yeda Research And Development Co., Ltd.	Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es)	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
KR100657048B1 (ko)	2001-12-04	2006-12-12	테바 파마슈티컬 인더스트리즈 리미티드	글라티라머 아세테이트의 효능 측정 방법
ES2289303T3 (es) *	2002-02-06	2008-02-01	Ares Trading S.A.	Factor de necrosis tumoral combinado con interferon en enfermedades desmielinantes.
PT1592384E (pt)	2003-01-21	2013-01-28	Yeda Res & Dev	Cop-1 para o tratamento de doenças inflamatórias do intestino
JP2006523683A (ja) *	2003-04-15	2006-10-19	オッパーバス・ホールディング・ビー・ブイ	タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
WO2005065291A2 (en) *	2003-12-31	2005-07-21	Genzyme Corporation	Enteric coated aliphatic amine polymer bile acid sequestrants
TW201240679A (en) *	2004-03-12	2012-10-16	Capsugel Belgium Nv	Pharmaceutical formulations
KR101347105B1 (ko) *	2004-06-25	2014-01-02	더 브리검 앤드 우먼즈 하스피털, 인크.	신경계 장애의 예방을 위한 조성물 및 방법
EP1797109B1 (de)	2004-09-09	2016-02-24	Yeda Research And Development Co., Ltd.	Mischungen von polypeptiden, zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung, und deren anwendungen
PL1799703T3 (pl)	2004-09-09	2010-06-30	Teva Pharma	Sposób wytwarzania mieszaniny polipeptydów stosując oczyszczony kwas bromowodorowy
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
CA2876966A1 (en)	2009-08-20	2011-02-24	Yeda Research And Development Co., Ltd.	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en)	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
WO2012051106A1 (en)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd.	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
CA2816957A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
ES2662373T3 (es)	2011-01-19	2018-04-06	Pathologica, Llc.	Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
AU2012323345A1 (en)	2011-10-10	2014-05-22	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
TW201420111A (zh)	2012-10-10	2014-06-01	Teva Pharma	對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
WO2014100639A1 (en) *	2012-12-21	2014-06-26	Teva Pharmaceutical Industries Ltd.	Transmucosal delivery of glatiramer acetate
JP6370804B2 (ja) *	2013-01-08	2018-08-08	パソロジカエルエルシー	脱髄疾患の治療のための方法および組成物
AU2014244550B2 (en)	2013-03-14	2018-11-01	Mylan Inc.	Glatiramer acetate response biomarker mRNA potency assay
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP2016533728A (ja) *	2013-10-24	2016-11-04	マイラン・インコーポレイテッドＭｙｌａｎＩｎｃ．	酢酸グラチラマー製品の免疫学的同一性を評価するためのヒトｔ細胞株アッセイ
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2018242998B2 (en)	2017-03-26	2023-11-02	Mapi Pharma Ltd.	Glatiramer depot systems for treating progressive forms of multiple sclerosis
US20200306516A1 (en) *	2017-08-14	2020-10-01	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800808A (en) *	1994-05-24	1998-09-01	Veda Research And Development Co., Ltd.	Copolymer-1 improvements in compositions of copolymers
IL119989A0 (en) *	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
CA2337688C (en) *	1998-07-23	2016-04-05	Yeda Research And Development Co., Ltd.	Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000020010A1 (en) *	1998-10-02	2000-04-13	Yeda Research And Development Co., Ltd.	Alternate day administration of copolymer 1 for treating autoimmune diseases

2001
- 2001-02-16 JP JP2001559488A patent/JP2003522799A/ja active Pending
- 2001-02-16 WO PCT/US2001/005198 patent/WO2001060392A1/en active IP Right Grant
- 2001-02-16 CA CA002400374A patent/CA2400374A1/en not_active Abandoned
- 2001-02-16 CN CNB018083021A patent/CN1221281C/zh not_active Expired - Fee Related
- 2001-02-16 MX MXPA02008023A patent/MXPA02008023A/es unknown
- 2001-02-16 IL IL15089501A patent/IL150895A0/xx unknown
- 2001-02-16 DE DE60120648T patent/DE60120648D1/de not_active Expired - Lifetime
- 2001-02-16 EP EP01910913A patent/EP1261361B1/de not_active Expired - Lifetime
- 2001-02-16 AU AU2001238469A patent/AU2001238469C1/en not_active Ceased
- 2001-02-16 AT AT01910913T patent/ATE329608T1/de not_active IP Right Cessation
- 2001-02-16 AU AU3846901A patent/AU3846901A/xx active Pending

Also Published As

Publication number	Publication date
AU2001238469B2 (en)	2005-11-03
ATE329608T1 (de)	2006-07-15
AU3846901A (en)	2001-08-27
IL150895A0 (en)	2003-02-12
CA2400374A1 (en)	2001-08-23
MXPA02008023A (es)	2005-06-30
EP1261361A4 (de)	2003-07-16
WO2001060392A1 (en)	2001-08-23
CN1221281C (zh)	2005-10-05
EP1261361B1 (de)	2006-06-14
CN1424915A (zh)	2003-06-18
AU2001238469C1 (en)	2006-08-24
EP1261361A1 (de)	2002-12-04
JP2003522799A (ja)	2003-07-29

Publication	Publication Date	Title
DE60120648D1 (de)	2006-07-27	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
NO952863D0 (no)	1995-07-19	Fluoxetin-farmasöytiske sammensetninger
IL152659A (en)	2010-12-30	Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
HUP0302131A2 (hu)	2003-12-29	Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
ITBO20050388A1 (it)	2006-12-07	Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
TR199800894T2 (xx)	1998-08-21	Biyo-yap��kan kat� dozaj formlar�.
HUP0302319A2 (hu)	2003-11-28	Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
HUP0301349A2 (hu)	2003-08-28	IL-11-tartalmú készítmények
IS4553A (is)	1997-08-27	Lyfjablöndur sem innihalda mónóamín oxídasa B blokkara
SE0102440D0 (sv)	2001-07-05	New compound
CA2340734A1 (en)	2000-06-22	Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
MXPA02011533A (es)	2003-04-25	Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
BR0014440A (pt)	2002-06-18	Formulações de liberação controlada oral
AU2173101A (en)	2001-07-03	Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
MXPA02006511A (es)	2004-08-11	Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
SE0000303D0 (sv)	2000-01-31	Novel compounds
CA2429793A1 (en)	2002-06-06	Interferon therapeutic effect enhancer
ATE371737T1 (de)	2007-09-15	Proteaseresistente flint-analoge
EP1429723A4 (de)	2005-06-15	Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies
BG105984A (bg)	2002-04-30	Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
MY131159A (en)	2007-07-31	New pharmaceutical compositions containing epinastine and pseudoephedrine
CA2436537A1 (en)	2002-05-10	Pharmaceutical compositions comprising tiotropium salts and antihistamines
ATE284696T1 (de)	2005-01-15	Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
PT1448220E (pt)	2008-10-15	Agente farmacêutico contendo uma substância activa antiflogística e hidrolisado de lactalbumina e respectiva utilização

Legal Events

Date	Code	Title	Description
2007-05-16	8332	No legal effect for de